Evidence map›Paper›PMID 36344934›Full record

ArticleBMC bioinformatics2022

Prediction of HIV-1 protease cleavage site from octapeptide sequence information using selected classifiers and hybrid descriptors.

Emmanuel Onah, Philip F Uzor, Ikenna Calvin Ugwoke, Jude Uche Eze, Sunday Tochukwu Ugwuanyi, Ifeanyi Richard Chukwudi, Akachukwu Ibezim

Abstract read
In one paragraph

Article in BMC bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emmanuel OnahDepartment of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka, Nigeria. emmanuel.onah.187260@unn.edu.ng.
Philip F UzorDepartment of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka, Nigeria.
Ikenna Calvin UgwokeDepartment of Pharmaceutical Microbiology and Biotechnology, University of Nigeria, Nsukka, Nigeria.
Jude Uche EzeDepartment of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Nigeria.
Sunday Tochukwu UgwuanyiDepartment of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria.
Ifeanyi Richard ChukwudiDepartment of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Nigeria.
Akachukwu IbezimDepartment of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka, Nigeria. akachukwu.ibezim@unn.edu.ng.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn most parts of the world, especially in underdeveloped countries, acquired immunodeficiency syndrome (AIDS) still remains a major cause of death, disability, and unfavorable economic outcomes. This has necessitated intensive research to develop effective therapeutic agents for the treatment of human immunodeficiency virus (HIV) infection, which is responsible for AIDS. Peptide cleavage by HIV-1 protease is an essential step in the replication of HIV-1. Thus, correct and timely prediction of the cleavage site of HIV-1 protease can significantly speed up and optimize the drug discovery process of novel HIV-1 protease inhibitors. In this work, we built and compared the performance of selected machine learning models for the prediction of HIV-1 protease cleavage site utilizing a hybrid of octapeptide sequence information comprising bond composition, amino acid binary profile (AABP), and physicochemical properties as numerical descriptors serving as input variables for some selected machine learning algorithms. Our work differs from antecedent studies exploring the same subject in the combination of octapeptide descriptors and method used. Instead of using various subsets of the dataset for training and testing the models, we combined the dataset, applied a 3-way data split, and then used a "stratified" 10-fold cross-validation technique alongside the testing set to evaluate the models.

resultsAmong the 8 models evaluated in the "stratified" 10-fold CV experiment, logistic regression, multi-layer perceptron classifier, linear discriminant analysis, gradient boosting classifier, Naive Bayes classifier, and decision tree classifier with AUC, F-score, and B. Acc. scores in the ranges of 0.91-0.96, 0.81-0.88, and 80.1-86.4%, respectively, have the closest predictive performance to the state-of-the-art model (AUC 0.96, F-score 0.80 and B. Acc. ~ 80.0%). Whereas, the perceptron classifier and the K-nearest neighbors had statistically lower performance (AUC 0.77-0.82, F-score 0.53-0.69, and B. Acc. 60.0-68.5%) at p < 0.05. On the other hand, logistic regression, and multi-layer perceptron classifier (AUC of 0.97, F-score > 0.89, and B. Acc. > 90.0%) had the best performance on further evaluation on the testing set, though linear discriminant analysis, gradient boosting classifier, and Naive Bayes classifier equally performed well (AUC > 0.94, F-score > 0.87, and B. Acc. > 86.0%).

conclusionsLogistic regression and multi-layer perceptron classifiers have comparable predictive performances to the state-of-the-art model when octapeptide sequence descriptors consisting of AABP, bond composition and standard physicochemical properties are used as input variables. In our future work, we hope to develop a standalone software for HIV-1 protease cleavage site prediction utilizing the linear regression algorithm and the aforementioned octapeptide sequence descriptors.

Indexed as

HIV-1HIV ProteaseAcquired Immunodeficiency SyndromeAlgorithmsBayes TheoremHIV InfectionsHIV Protease InhibitorsHumansHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1Amino acid binary profileBond compositionCleavage siteHIV-1 proteaseMachine learningNumerical descriptorsOctapeptide sequencePhysicochemical propertiesStratified 10-fold CV

Identifiers

PMID36344934
PMCPMC9641908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.